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To engineer gene vectors that target striated muscles after sys-
temic delivery, we constructed a random library of adeno-associ-
ated virus (AAV) by shuffling the capsid genes of AAV serotypes 1
to 9, and screened for muscle-targeting capsids by direct in vivo
panning after tail vein injection in mice. After 2 rounds of in vivo
selection, a capsid gene named M41 was retrieved mainly based on
its high frequency in the muscle and low frequency in the liver.
Structural analyses revealed that the AAVM41 capsid is a recom-
binant of AAV1, 6, 7, and 8 with a mosaic capsid surface and a
conserved capsid interior. AAVM41 was then subjected to a side-
by-side comparison to AAV9, the most robust AAV for systemic
heart and muscle gene delivery; to AAV6, a parental AAV with
strong muscle tropism. After i.v. delivery of reporter genes,
AAVM41 was found more efficient than AAV6 in the heart and
muscle, and was similar to AAV9 in the heart but weaker in the
muscle. In fact, the myocardium showed the highest gene expres-
sion among all tissues tested in mice and hamsters after systemic
AAVM41 delivery. However, gene transfer in non-muscle tissues,
mainly the liver, was dramatically reduced. AAVM41 was further
tested in a genetic cardiomyopathy hamster model and achieved
efficient long-term -sarcoglycan gene expression and rescue of
cardiac functions. Thus, direct in vivo panning of capsid libraries is
a simple tool for the de-targeting and retargeting of viral vector
tissue tropisms facilitated by acquisition of desirable sequences
and properties.
Muscular dystrophies are a class of debilitating and often lethalgenetic diseases because of the lack of effective treatment.
Cardiomyopathy is a commonly associated pathology a main cause
of premature death of the patients (1). Gene therapy for muscular
dystrophy and cardiomyopathy has been actively investigated as a
promising and viable therapeutic approach (2). Gene vectors based
on adeno-associated virus (AAV) are the most efficient vector
systems currently available for gene delivery in the muscle and heart
(3–8). To realize significant benefits in muscular dystrophy patients,
efficient systemic therapeutic gene delivery into striated muscles
throughout the body is highly desirable. The recently identified new
AAV serotypes, e.g., AAV6, 7, 8, and 9, are able to serve such a
purpose after i.v. injection in animal models (5, 6, 9–12). None-
theless, those vectors also exhibit broad tissue tropism, especially in
the liver, which is a major depot for AAV vectors upon intravascular
administration (5, 13). The unintended gene transfer to the liver
and other tissues remains a concern for muscle-oriented systemic
gene delivery. As a result, de-targeting AAVs from the non-muscle
tissues and retargeting them to the muscle and heart could reduced
unwanted side effects in muscle gene therapy.
The AAV genome contains 2 viral genes, rep (replication) and
cap (capsid). The cap gene encodes 3 overlapping capsid proteins
VP1, VP2, and VP3. A large number of AAV serotypes and variants
have been isolated from human and non-human primates with
substantial sequence diversity among their cap genes (12, 14). These
AAV serotypes exhibit different infectivities on various tissues.
Three-dimensional (3D) structure and mutagenesis studies of sev-
eral AAV serotypes have shown that the common capsid region
displays an 8-stranded (bB-bI) core -barrel motif with loop
insertions, which are the main determinants of AAV serotype-
specific properties, such as receptor recognition, transduction ef-
ficiency and antigenic reactivity (15–17). The structural information
on the capsid forms the basis for genetic engineering of novel AAV
vectors. DNA shuffling has recently been used to modify viral
vectors (18, 19) by introducing enormous permutations of genetic
variations via in vitro recombination. The shuffled AAV mutant
libraries were used for selection of desirable features such as
resistance to antibody neutralization (19, 20) and improved tropism
to cancer cells (21). In the above studies, however, in vitro bio-
panning on cultured cells was the first, and often the only, selection
accompanied by intrinsic bias and limitations. No results have been
reported on direct in vivo selection of AAV mutant capsides
libraries after systemic administration.
In this study, we genetically engineered an AAV cap gene library
by DNA shuffling of different AAV serotype capsid genes. The
library was directly screened in mice in vivo. AAV capsids were
selected by their combined capacity of crossing the tight vasculature
barriers in muscle tissues and infectivity to muscle cells. One of the
mutant AAV vectors named AAVM41 was found to exhibit
enhanced infectivity to cardiac muscle and diminished infectivity to
the liver after systemic administration. Further testing of AAVM41
in a heart failure hamster model verified its efficiency and efficacy
in therapeutic gene transfer, and demonstrated the usefulness of
capsid gene DNA shuffling and direct in vivo selection.
Results
Direct In Vivo Panning of DNA-Shuffled AAV Library for Muscle-
Targeting Capsids. We constructed a chimeric AAV library by DNA
shuffling of the capsid genes of AAV1, 2, 3, 4, 6, 7, 8, and 9, to select
for combined characteristics. The infectious AAV library with
shuffled capsid genes was packaged by the method of Muller et al.
(22). DNA analysis by restriction digestions on randomly picked
mutant AAV clones showed unique patterns and indicated that the
vast majority of them were recombinants viable in producing AAV
particles.
Although it is a common practice to use in vitro cell culture
systems to screen for desirable mutant AAVs, here we solely relied
on a direct in vivo screening method, because no cell culture system
could simultaneously mimic the in vivo conditions (e.g., the tight
endothelial lining, the differentiated muscle cells and the liver). We
used adult mice for in vivo bio-panning of the AAV library. After
tail vein injection of a dose of 5  1011 v.g. (viral genomes), the
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AAV cap genes that were enriched in the muscles were retrieved by
PCR amplification. In the first round of in vivo screening, 43 distinct
AAV clones were identified. They were mixed in equal ratio for
secondary AAV library production and second-round in vivo
screening. The clones enriched in the muscle but scarce in the liver
were further characterized.
A clone named M41 appeared 12 times in 79 randomly picked
clones from the muscle pool but was absent in the liver pool (Table
S1). Sequence alignment of its capsid amino acid sequence showed
that it is a recombinant of 4 parental AAV serotypes, AAV1, 6, 7,
and 8. The N-terminal half of the capsid is from AAV1, 8, and 7,
while the C-terminal half is from AAV6 and 1 (Fig. 1A). To deduce
the contributions of the 4 parental serotypes, a 3D homologous
structural model of M41 capsid was generated, using residues 211
to 736 of its overlapping VP1-VP3 region, by aligning its sequence
with those of the parental serotypes. Both the exterior and interior
surfaces of the capsid clearly showed the presence of segments from
the 4 parental AAV capsids (Fig. 1 B and C). On the capsid surface,
the DE loop of AAV7 forms the -ribbons that assemble a
channel at the icosahedral 5-fold axis, while AAV6 sequences form
the HI loop which lies on AAV7 sequences forming the floor of the
depression surrounding this axis (Fig. 1B, frame a). Three GH
loops with sequences from AAV1 and AAV6 interact to form the
characteristic protrusions that surround the icosahedral 3-fold
symmetry axis on the surface of the AAV capsid (15), with the
sub-loop from AAV1 closer to the axis (Fig. 1B, frame b). The BC
loop from AAV7 and the region following I of AAV6 form the
wall between the 5- and 2-fold axes, with AAV6 forming the
depression at the 2-fold axis (Fig. 1B, frame c). In contrast to the
relatively complicated sequence composition on the exterior sur-
face of the AAVM41 capsid, its interior surface was mostly
composed of barrel -strands from AAV7 and strand I from
AAV6 (Fig. 1C). The few residues from AAV8 participated in the
assembly of the region of the channel at the 5-fold symmetry axis
located in the interior of the capsid (Fig. 1C). This analysis
highlighted the unique structural properties of the AAVM41 capsid
arising from the parental serotypes.
M41 Vector Preferentially Transduces Myocardium After Systemic
Administration. We next investigated systemic gene delivery effi-
ciency and tissue tropism of AAVM41. The luciferase reporter gene
was packaged into viral capsids of M41, AAV9, and AAV6 for a
side-by-side comparison in vivo. At 2 weeks post i.v. injection in
young adult C57BJ/6L mice (6–8 wks), luciferase activities and
vector DNA copy numbers in various tissues were analyzed. Con-
sistent with previous reports (13), the AAV9 vector efficiently
transduced mouse heart, skeletal muscles, and particularly the liver,
which had the highest luciferase activity (Fig. 2A) and vector DNA
copy numbers (Fig. 2B). Similar to AAV9, the M41 vector also
transduced the heart efficiently with slightly lower luciferase activity
and vector copy numbers (Fig. 2B). However, M41 showed dra-
matically reduced gene transfer in the liver, with the luciferase
activity 81.1-fold lower and DNA copy number 11.3-fold lower than
AAV9. However, AAVM41 gene transfer in the skeletal muscles,
except in the tongue, was also significantly lower than AAV9 (Fig.
2A). Interestingly, although the liver had higher DNA copy num-
bers (Fig. 2B), the heart showed the highest luciferase activity
among all tissues examined in M41 injected mice (Fig. 2A),
suggesting differential intracellular trafficking and uncoating pro-
cesses of AAVM41 in these 2 tissues.
Similar side-by-side comparison between AAVM41 and AAV6
at 2 weeks after i.v. injection revealed higher gene transfer by
AAVM41 in all skeletal muscles, and dramatically higher gene
transfer (13-fold) in the heart (Fig. 2C), but 50% reduction in
the liver. Interestingly, although AAV6 had significantly higher
vector DNA copy numbers than AAVM41 in some muscle tissues
such as the tibialis anterior and quadriceps (Ta and Qd in Fig. 2D),
the gene expression levels were much lower. The inconsistency in
vector genome quantity and transgene expression between these 2
viruses suggests a more complex difference in vector bioavailability
in the muscle tissues, such as transcytosis through endothelial lining
and preferential infection of muscle rather than non-muscle cells.
Since 1 important aim of this study was to reduce liver infectivity,
we compared ratios of heart vs. liver gene expression for the above
3 AAVs. While the heart vs. liver ratio of AAVM41 was 10:1, this
ratio was reversed to 1:3 in AAV9 and 1:6 in AAV6 (Fig. 2E).
Consistently, the ratios of heart vs. liver vector DNA copy numbers
also showed a similar trend to the luciferase activities among the 3
AAVs (Fig. 2F). These data thus demonstrated improved tropism
to the heart and much reduced tropism to the liver by AAVM41.
We next used -galactosidase (LacZ) reporter gene to directly
visualize transgene expression in cardiomyocytes and myofibers. At
2 weeks post vector i.v. injection in adult C57BJ/6L mice, approx-
imately one-half of the cardiomyocytes in the heart showed positive
Fig. 1. Sequence and structure analysis of the M41
capsid. (A) The primary structure of M41 capsid by align-
ments of its VP1 amino acid sequence with those of the
parental AAV serotypes. A D to Y substitution on residue
418 is shown by a triangle. (B and C) The structural model
of the 9-mer AAVM41 VP3 subunits reconstructed from
the known crystal and homologous model structures of
the parental viruses with the exterior surface (B), and
interior surface (C), respectively. Sequences derived from
AAV1 are colored in purple, AAV6 in hot pink and light
pink (2 segments), AAV7 in cyan, AAV8 in green. The axes
of symmetry are shown by white pentagon (5-fold), trian-
gle (3-fold) and oval (2-fold) on the structural models. The
structural regions around them are highlighted by frames
a, b, and c.











X-gal staining in AAV9- and AAVM41-treated mice (Fig. 3). A
similar test was also performed in hamsters, a different and larger
species. At 3 weeks post i.v. injection into adult F1B hamsters,
nearly 100% of the cardiomyocytes showed positive X-gal staining
in both AAV9- and AAVM41-treated groups (Fig. 3). Quantitative
enzyme assays showed nearly identical levels of LacZ expression in
the hearts of AAV9- and AAVM41-treated mice as well as
hamsters. In the skeletal muscles of the above mice and hamsters,
however, AAVM41 was much less efficient than AAV9 (Fig. 3B).
These results are consistent with those of luciferase reporter gene
transfer, suggesting preferential targeting of AAVM41 to the
myocardium.
Direct Infection of Cardiomyocytes and Skeletal Muscle by M41
Vector. Since AAVM41 was initially isolated from the muscle but
showed best infectivity to the heart after systemic delivery, we
wished to examine the direct infectivity of AAVM41 on primary
cardiomyocyte culture or on skeletal muscles by intramuscular
injection. The AAV-LacZ vectors packaged by AAVM41, AAV6
and AAV9 were used to infect primary cardiomyocytes isolated
Fig. 2. Luciferase activities and vector genome copy numbers in various mouse tissues after systemic administration of AAV vectors. Comparison of AAV9- and
AAVM41-CMV-Lucvectors in luciferaseactivities (A), andAAVvectorgenomecopynumbers (B), at2-weeksafter i.v. injectionof31011 vectorgenomes inmice.Similar
comparison of AAV6- or M41-CMV-Luc vectors in luciferase activities (C), and AAV genome copy numbers (D). Data are mean values  SD. Ab, abdomen muscle; Di,
diaphragm; Ta, tibialis anterior; Ga, gastrocnemius; Qd, quadriceps; Fl, forelimb; Ma, masseter; Ht, heart; Lv, liver; Sp, spleen; Kd, kidney; Lu, lung; Pa, pancreas; Te, testis;
Br, brain; Tg, tongue. Heart vs. liver ratio in transduction efficiency by 3 rAAV vectors on luciferase activities (E), and vector genome copy numbers (F).
Fig. 3. Systemic delivery of LacZ transgene by
AAVM41 into striated muscles. (A) X-gal staining of
cross-sections of hearts after systemic administration
of AAV vectors. 3  1011 vector genomes of AAV9- or
M41-CB-LacZ were injected via tail vein into adult mice;
and 1  1012 vector genomes of AAV9- or M41-CMV-
LacZ were injected via jugular vein into adult hamsters.
Hearts from mice or hamsters were collected at
2-weeks or 3-weeks post injection for X-gal and eosin
staining. Two magnifications (4 and 40) were used
for photography. (B) Lacz transgene expression in the
tibialis anterior muscles of the same animals as de-
scribed in (A). [Scale bars: A, 200 m (4) and 50 m
(40); B, 100 m.]
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from neonatal rats. Four days later, 1% of the AAV9-infected
cardiomyocytes expressed the LacZ gene, but 20% and 80% of
the M41 and AAV6 cells, respectively, expressed the LacZ gene
(Fig. 4A Upper). Quantitative analysis showed that -gal enzyme
activities of AAVM41- and AAV6-infected cardiomyocytes were
2.8-fold and 6.2-fold, respectively, of that of AAV9 (Fig. 4B).
Similarly, the vector copy numbers in the cells were 2.3- and
10.3-fold of that of AAV9 (Fig. 4C). These data indicated that
AAVM41 infectivity for cardiomyocytes was higher than AAV9 but
lower than AAV6.
The above 3 AAV-LacZ vectors were then injected into mouse
gastrocnemius muscle for comparison of skeletal muscle infectivi-
ties. Two weeks later, X-gal staining of the muscle cryosections
revealed the strongest expression by AAV6, intermediate expres-
sion by AAVM41 and weak expression by AAV9 (Fig. 4A, lower
panels). Quantitative -gal activities of AAV6-injected muscles
were 6.1-fold and 53.8-fold of that of AAVM41 and AAV9,
respectively (Fig. 4D). Together with the in vitro cardiomyocytes
infection data, these results strongly suggest that the much im-
proved systemic muscle and heart gene delivery by AAVM41 over
AAV6 is most likely due to improved capability of crossing the tight
endothelial barrier and reaching muscle cells.
Application of M41 in a Cardiomyopathy and Congestive Heart Failure
Hamster Model. Since AAVM41 showed preferential gene transfer
in the heart, we next investigated the utility of this vector for gene
therapy in a genetic cardiomyopaty and muscular dystrophy model,
the -sarcoglycan (-SG) deficient TO-2 hamsters (9, 23). Four
months after i.v. injection of 1  1012 v.g. of AAVM41-SG vector,
SG expression was detected predominantly in the heart by immu-
nofluorescent (IF) staining (Fig. 5A). Nearly 100% of the cardio-
myocytes showed strong and uniform -SG expression. However,
only 10–30% of the skeletal muscle myofibers expressed -SG, as
shown in the forelimb, tibialis anterior and tongue muscles. Western
Fig. 4. Comparison of gene transfer efficiency in primary cardiomyocytes or skeletal muscles. (A) Representative X-gal staining of cardiomyocytes or skeletal
muscle after transduction by AAV9-, AAVM41-, or AAV6-CMV-LacZ vectors. The AAV vectors were inoculated on the primary neonatal rat cardiomyocytes (5 
105 cells per well) at an infection multiplicity of 3,000. Cells were fixed for X-gal staining 96 h later (Upper). The AAV vectors (5  109 v.g.) were also injected
into the gastrocnemius muscle of adult C57BJ/6L mice and tissues were sectioned and stained with X-gal and eosin 14 days post-treatment (Lower). (Scale bars,
100 m.) (B and C) Quantitative -gal activities and AAV vector genome copies in primary cardiomyocytes; and (D) -gal activities in mouse skeletal muscles. Data
are shown as mean values  SD.
Fig. 5. Systemic delivery of -sarcoglycan into cardiomyopathic hamster for treatment of heart failure. Totals of 1  1012 vector genomes of M41-Syn-SG vector
were injected into 7-week-old male TO-2 hamsters via the jugular vein (n  5). (A) Immunofluorescent staining of -sarcoglycan on thin sections of heart and
skeletal muscle tissues 4 months after vector administration. Two magnifications were used for clear view. (Scale bars, 50 m.) (B) Western analysis of
-sarcoglycan in muscle and non-muscle tissues from untreated TO-2 (-) and rM41 vector-treated TO-2 () hamsters. Twenty micrograms of total proteins were
loaded in each lane. (C) Amelioration of cardiomyopathy in TO-2 hamsters after -sarcoglycan gene transfer. Hamster hearts of wild-type F1B, untreated TO-2
and AAVM41-SG-treated TO-2 were cryosectioned and stained with different methods for histology and pathology. Arrows and arrowheads indicate fibrosis
and calcification, respectively. (Scale bars, 100 m.)











blot analysis confirmed strongest expression of -SG in the heart
(Fig. 5B). No -SG expression was detected in the non-muscle
tissues, including the liver. The muscle-specific, heart-preferential
transgene expression was accompanied by the lack of immune
rejection or toxicity throughout the duration of the experiments.
We also evaluated the therapeutic efficacies of AAVM41--SG
treatment in the TO-2 hamsters, which manifest both cardiomyop-
athy and muscular dystrophy. First, we measured serum levels of
muscle creatine kinase activities and found no statistically signifi-
cant difference between the treated and untreated groups, suggest-
ing insufficient therapeutic gene transfer in the skeletal muscles by
AAVM41. This is consistent with the IF staining results (Fig. 5A).
We continued to examine the therapeutic efficacy on cardiomyop-
athy. Upon necropsy, gross examination of the untreated control
TO-2 hamster hearts showed marked dilation and prominent
calcification plaques. In contrast, the hearts of the treated TO-2
hamsters exhibited normal gross morphology, similar to those of
wild-type control F1B hamsters. Histological staining further re-
vealed large areas of cardiomyocyte degeneration (Fig. 5C, left
panel), fibrosis (Fig. 5C, middle panel) or calcification (Fig. 5C,
right panel) in the untreated TO-2 hamsters. However, those
pathological signs were dramatically reduced or completely dimin-
ished in the AAVM41-treated hamster hearts. Echocardiography
examination of the treated TO-2 hamsters also showed great
improvement on all major parameters of cardiac functions, includ-
ing left ventricle end-systolic dimension, percentage fractional
shortening, and left ventricle posterior wall thickness, nearly iden-
tical to those of wild-type F1B hamsters, but significantly different
from those of the untreated TO-2 hamsters (P  0.05 by Student’s
t test) (Fig. S1). These data further demonstrated the therapeutic
efficacy by AAVM41 gene delivery in improving cardiac functions
of TO-2 hamsters.
Resistance of M41 to Pre-Existing Neutralizing Antibodies in Pooled
Human IgGs. Last, we investigated AAVM41 for its resistance to
pre-existing neutralizing antibodies. Commercially available human
IVIG (pooled human IgGs for i.v. use) was used as the source of
antibodies (19, 20, 24, 25). AAVM41 was compared with AAV2,
the best characterized serotype, and AAV8, a new isolate with low
prevalence of pre-existing antibodies in human population (24, 25).
The AAV2-, AAV8-, and AAVM41-LacZ vectors were pre-
incubated with serial dilutions of IVIG, inoculated on Huh7 cell
culture for 4 days and then assayed for LacZ expression as an
indicator of vector resistance to neutralization (see SI Materials and
Methods for details). At 1:64 dilution of IVIG, AAV2 infectivity
decreased to 33%  4% of its control without IVIG. However,
AAV8 and AAVM41 infectivities remained at 94%  4% and
83%  1% of their controls. Even at the highest IVIG concentra-
tion (1:8 dilution), AAV8 and AAVM41 still retained 33%  12%
and 26%  3% of their infectivities, while AAV2 was nearly
completely neutralized under the same condition (Fig. S2).
Discussion
The purpose of this study was to retarget and optimize the tissue
tropism of AAV vectors for striated muscles upon systemic delivery.
Natural AAV1 and 6 are highly efficient in directly infecting striated
muscles by local intramuscular (26, 27) or intramyocardial injection
(28, 29), whereas AAV7, 8, and 9 are highly efficient in crossing the
endothelial barriers in muscle and heart (5, 6, 30). To engineer
vectors with combined properties, we generated AAV capsid gene
libraries by DNA shuffling and performed direct in vivo selection.
The major advantage of our study is the avoidance of bias and
limitation of in vitro panning. We demanded simultaneous selec-
tion for viruses that are (i) efficient in crossing the endothelial
barriers in the striated muscles; (ii) efficient in infecting muscle
cells; and 3) poor in infecting the liver and other non-muscle cells.
Direct in vivo screening and selection appeared to be the most
desirable and feasible strategy. To this end, we have indeed
successfully generated a AAV capsid AAVM41, displaying mosaic
capsid exterior surface with enhanced tropism to the striated
muscles, especially the heart, and diminished infectivity to the liver.
The AAVM41 capsid achieved up to 13-fold improvement in the
heart and several fold in the skeletal muscle by systemic gene
transfer over its parental AAV6, which comprised a major portion
of the C-terminal half of the capsid (Fig. 1). In addition, AAVM41
showed similar infectivity to the heart but a dramatic reduction to
the liver, when compared to AAV9, the most efficient AAV vector
for cardiac gene transfer by the systemic route. Despite the fact that
AAVM41 showed diminished infectivity to the liver (Fig. 2), it is far
from ideal. To further improve de-targeting AAVs from the liver,
increasing selection stringency and specificity during in vivo pan-
ning, retrieving mutant AAVs from isolated cardiomyocytes or
myofibers, instead of the whole tissue which contains a variety of
non-muscle cells, could further enhance the screening efficiency.
The use of extremely high-diversity libraries as the starting material
by a combination of DNA shuffling and error-prone PCR could
also increase the rate of success (19).
The precise mechanisms on how the liver and heart tropisms
were altered for AAVM41 remain to be elucidated. We attempt to
find explanations by analyzing its structural features contributed by
the parental AAV serotypes (Fig. 1). The exterior surface of the
AAVM41 viral particle was composed of loops from serotypes
AAV1, 6, and 7 (Fig. 1B). The capsid surface should gain new
properties on receptor/coreceptor binding and intracellular traf-
ficking, thus, leading to the altered cell and tissue tropisms. The
capsid C-terminal regions acquired from AAV1 and 6 may have
played a crucial role in infectivity to the striated muscles, both
skeletal and cardiac, whereas the N-terminal regions acquired from
AAV7 and 8, mainly AAV7, may have improved systemic gene
delivery with enhanced transcytosis across the endothelial cell
lining (5, 31). While the AAV6 might stay in endothelial cells after
intravascular delivery, AAVM41 could transcytose into the ex-
travascular space and efficiently infect muscle cells. Characteriza-
tion of AAVM41 interaction with endothelial and muscle cells and
potential cellular receptors should shed light on its evolution and
future improvement. Finally, the myocardium specificity can be
strengthened by the use of cardiac-specific promoters, and resis-
tance of AAVM41 to pre-existing antibodies could be further
enhanced by additional selections (19, 20).
Materials and Methods
Generation of Chimeric AAV Library with Shuffled Capsid Genes. For construc-
tion of random chimeric AAV capsid gene libraries, AAV serotypes 1, 2, 3B, 4, 6,
7, 8, and 9 were used as PCR templates. The capsid genes were amplified by
primers CAP-5 (5-CCC-AAGCTTCGATCAACTACGCAGACAGGTACCAA-3) and
CAP-3 (5-ATAAGAAT-GCGGCCGC-AGAGACCAAAGTTCAACTGAAACGA-3)
and mixed in equal ratio for DNA shuffling (18). In brief, 4 g of the DNA
templates were treated by 0.04 U of DNase I at 15 °C briefly. DNA fragments in
size of 300–1,000 bp were purified by agarose gel electrophoresis, denatured,
reannealed and repaired by pfu DNA polymerase to reassemble random capsid
genes. Amplification was done by use of pfu DNA polymerase and CAP5/CAP3
primers. The PCR program was 30 cycles of 94 °C 1 min, 60 °C 1 min and 72 °C 4.5
min. The PCR products were then digested with HindIII and NotI and ligated into
a HindIII and NotI digested plasmid backbone containing AAV2 Rep gene and
inverted terminal repeats. The random infectious plasmids library was obtained
by transforming the above ligated DNA into DH10B E. coli cells. Random clones
were picked for restriction enzyme analysis and replication and packaging via-
bility in 293 cells. The shuffled infectious AAV library was finally produced using
a self-packaging technique developed by Muller et al. (22).
In Vivo Bio-Panning of Mutant AAV Capsid Library in Mice. A dose of 5  1011
vector genomes of the chimeric AAV library were injected into adult C57BL/6J
mice via tail vein. Three days later, mice were killed and perfused with PBS to
remove the blood from tissues. The hind limb skeletal muscles and liver were
collected for total DNA isolation. The capsid genes enriched in the muscle were
retrieved by PCR amplification using primers Cap 5 and Cap 3 and the iProof
DNA polymerase (Bio-Rad). The PCR products were digested with HindIII and NotI
and cloned similarly as described in previous section. The 43 representative AAV
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capsid genotypes were identified from the reconstructed plasmid library by
restriction analysis and mixed in equal ratio for production of a secondary AAV
library as described earlier. This AAV library was again injected i.v. in mice for
secondary screening and retrieval from muscle and liver. Random colonies were
sequenced and compared for their tissue distribution.
Sequence and Structure Analyses of Modified AAV Capsid Genes. Identification
and alignment of the capsid genes from the mouse tissues was done using Clustal
X (32). A 3D homology model of the VP3 structure of AAVM41 was generated
from the coordinates of the crystal structures of AAV1, AAV7, and AAV8 (17) and
a homology model of AAV6 (33), the parental viruses, using the Coot program
(34). After superimposition of these template coordinates, the chimeric M41 VP3
structural model was generated by manual cutting and pasting of the appropri-
ate amino acid sequences from each serotype and regularization of the model
geometry. To visualize the contribution of each serotype in the context of the
assembled M41 capsid icosahedral 2-, 3-, and 5-fold symmetry operators were
appliedtotheVP3model coordinatesbymatrixmultiplicationusingtheprogram
O (36). The serotype segments were then highlighted in the context of 9 VP3
monomerswhichsurround1viralasymmetricunit inasurfacerendereddepiction
generated using the program PyMol (35).
Tissue Tropism of AAV Vectors in Mice after Systemic Administration. The M41
capsid gene was used to package CMV-luciferase, CB-LacZ, or CMV-LacZ reporter
vectors for comparison with the AAV9 or AAV6 packaged ones. Three  1011 v.g.
of reporter vectors containing CMV-luciferase or CB-LacZ genes were injected i.v.
into 6- to 8-week-old C57BL/6J mice for systemic gene delivery and expression.
The heart, skeletal muscle and main internal organs of mice were collected 2
weeks later. Reporter gene expression was monitored by luciferase assay (Lucif-
eraseAssaySystem;Promega)or-galassay (Galacto-LightPlus™system;Applied
Biosystems). Cryosectioning and X-gal staining were used to visualize cells that
expressed the LacZ in the heart and muscle. Total DNA was extracted from mouse
tissues for quantitative detection of vector genome copies by Taqman probes
(AppliedBiosystems)withasingle-copyendogenousgene(glucagongene)as the
diploid cell number reference.
Transduction of Primary Cardiomyocytes or Skeletal Muscle by AAV Vectors. Rat
neonatal cardiomyocytes were isolated and cultured as previously reported (37).
Twenty-four hours after preplating, rAAV9-, rM41-, or rAAV6-CMV-lacZ vectors
were inoculated onto the cardiomyocytes in infection multiplicity of 3000. Cells
were fixed for X-gal staining or -gal assay after another 96 h to detect transgene
expression. For skeletal muscle transduction, 50 L of virus dilutes containing 5 
109 v.g. of rAAV vectors were intramuscularly injected into gastrocenemius
muscles of adult 7-week-old C57BJ/6L mice. Fourteen days later muscle tissues
were collected for detection of transgene expression by X-gal staining or -gal
assay. Vector genome distribution in cardiomyocytes or skeletal muscles was
quantitated by real-time PCR as described.
Gene Transfer and Functional Assays in the Hamster Models. Tropism of the
vectors in hamsters was first investigated in the normal F1B hamsters. A dose of
1012 vector genomes of M41-CMV-lacZ or AAV9-CMV-lacZ was administered into
2- to 3-month-old male F1B hamsters via the jugular vein. Three weeks later,
heart, skeletal muscles, and the internal organs, including the liver, were col-
lected for histological staining. The synthetic muscle-specific promoter (SYN)
C5–12 was used to achieve strong and muscle-specific -SG transgene expression
in the TO-2 hamsters (9). A dose of 1012 vector genomes of the M41-SYN-SG
vectors were administered into 7-week-old male TO-2 hamsters intravenously
with untreated TO-2 or with normal F1B hamsters as the control groups. Char-
acterizations of Sarcoglycan expression, histology examination, and function test
were done according to the previous publication (9).
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